Rosiglitazone

CHF 40.00
In stock
AG-CR1-3570-M01010 mgCHF 40.00
AG-CR1-3570-M02525 mgCHF 80.00
AG-CR1-3570-M100100 mgCHF 200.00
AG-CR1-3570-G0011 gCHF 490.00
More Information
Product Details
Synonyms BRL 49653; HSDB 7555; TDZ 01
Product Type Chemical
Properties
Formula

C18H19N3O3S

MW 357.4
Merck Index 14: 8265
CAS 122320-73-4
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO, ethanol or methanol.
Identity Determined by IR and 1H-NMR.
InChi Key YASAKCUCGLMORW-UHFFFAOYSA-N
Smiles CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antidiabetic, hypoglycemic agent [1, 5].
  • Potent and selective peroxisome proliferator-activated receptor γ (PPAR-γ) agonist [2, 3].
  • Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance [4-6, 8].
  • Improves blood pressure and vascular function [7].
  • Enhances proliferation of endogenous neural progenitor cells (NPCs) [9].
  • Anti-inflammatory compound [10, 11].
  • Has controversial therapeutic effects on the cardiovascular system [12].
  • Promotes adipocyte differentiation of mesenchymal stem cells (MSCs) [13].
Product References
  1. [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
  2. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ): J.M. Lehmann, et al.;  J. Biol. Chem. 270, 12953 (1995)
  3. Rosiglitazone: J.A. Balfour & G.L. Plosker; Drugs 57, 921 (1999) (Review)
  4. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes: G.A. Knock, et al.; Eur. J. Pharmacol. 368, 103 (1999)
  5. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes: A. Cheng-Lai & A. Levine; Heart Dis. 2, 326 (2000) (Review)
  6. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review: J.M. Malinowski & S. Bolesta; Clin. Ther. 22, 1151 (2000) (Review)
  7. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice: M.J. Ryan, et al.; Hypertension 3, 661 (2004)
  8. Rosiglitazone: a review of its use in type 2 diabetes mellitus: E.D. Deeks & S.J. Keam; Drugs 67, 2747 (2007) (Review)
  9. Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury: Q.Q. Meng, et al.; Neurosci. Lett. 503, 191 (2011)
  10. Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells: W.M. Wang, et al.; Am. J. Nephrol. 34, 152 (2011)
  11. PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway: Y. Ji, et al.; Cytokine 55, 409 (2011)
  12. PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? S. Palee, et al.; World J. Cardiol. 3, 144 (2011)
  13. Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line: D. Wang, et al.; Biomed. Sci. Instrum. 47, 213 (2011)
  14. ROCK2 inhibition enhances the thermogenic program in white and brown fat tissue in mice: L. Wei, et al.; FASEB J. ahead of print (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.